Humonix Biosciences Names Karen Torrejon, PhD as CEO

Humonix Biosciences, a pioneering biotechnology company, has recently named Dr. Karen Torrejon as its new Chief Executive Officer. Dr. Torrejon, who originally founded the company in 2014, will now lead its operations as it transitions into a broader, science-driven platform.

Innovative 3D Human Tissue-Based System

The foundation of Humonix's platform lies in its proprietary 3D human tissue-based system, initially developed for studying glaucoma under the Glauconix name. This innovative system has since expanded to encompass a range of disease entities, including retinal vascular disease, pulmonary fibrosis, and renal fibrosis.

Enhancing Drug Development

As a strategic partner to pharmaceutical and biotechnology firms, Humonix plays a pivotal role in enhancing the drug development process. By leveraging validated human tissue models, the company accelerates the translation of preclinical research into human efficacy, thereby reducing costs and increasing the likelihood of program success. Furthermore, Humonix's ex vivo system contributes to a deeper understanding of therapeutic mechanisms while aligning with the FDA's Modernization Act 2.0, which emphasizes the reduction of animal testing.

Dr. Torrejon expressed her enthusiasm about leading Humonix Biosciences into its next phase of growth, stating, "I am excited to once again lead the company that I founded a decade ago as we now expand into broader disease models as Humonix Biosciences." She also acknowledged the contributions of Ms. Southern in establishing Glauconix's presence in the contract research space.

Dr. Torrejon highlighted the company's unique capability to test compounds in human tissues ex vivo, distinguishing Humonix and enabling the early identification of promising candidates for further development.